24/7 Market News Snapshot 04 November, 2024 – KalVista Pharmaceuticals, Inc. Common Stock (NASDAQ:KALV)

November 4, 2024

DENVER, Colo., 04 November, 2024 (247marketnews.com) – (NASDAQ:KALV) are discussed in this article.
KalVista Pharmaceuticals, Inc. has made significant strides in the market, opening today at $11.30 and experiencing a notable surge to $11.70, reflecting an impressive intraday increase of approximately 10.26% following a previous close of $10.61. This surge indicates strong investor interest, highlighted by a trading volume of 501.08K shares, suggesting a bullish sentiment among traders. As the company navigates this upward trajectory, it experiences a technical breakout above recent resistance levels, prompting investors to watch for potential further gains while noting critical support around $11.30 and resistance at $12.

In addition to the favorable market activity, KalVista Pharmaceuticals has announced the successful pricing of an underwritten offering of 5,500,000 shares of its common stock at $10.00 per share, aiming to raise approximately $55 million in gross proceeds. This capital is essential for advancing its ongoing clinical development initiatives. Furthermore, the company has secured a private placement agreement with DRI Healthcare Acquisitions LP for an additional 500,000 shares, raising an additional estimated $5 million. The proceeds from both offerings are poised to enhance KalVista’s resources for the clinical development of its lead candidate, sebetralstat, particularly as it prepares for potential commercialization following regulatory approval.

Both the public offering and the private placement are anticipated to close on November 5, 2024, subject to customary closing conditions. KalVista remains dedicated to addressing unmet medical needs with innovative therapies, particularly as it progresses through the regulatory landscape. Its New Drug Application (NDA) for sebetralstat, aimed at treating hereditary angioedema (HAE) attacks on demand, has been accepted by the U.S. Food and Drug Administration, with a projected goal for final agency action set for June 17, 2025. The strategic initiatives reflect KalVista’s commitment to sustainable growth and improving patient outcomes through effective treatment solutions.

Related news for (KALV)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.